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Recombinant activated factor VII (rFVIIa) was ori-
ginally designed for the treatment of bleeding epi-
sodes in haemophilia patients who had inhibitors. It
has since been used for other coagulopathic states
such as thrombocytopenia and Von Willebrand’s
disease, and in liver transplantation.3,6 More
recently it has been used for severe bleeding in
non coagulopathic patients.
Factor VIIa is thought to act only at the site of
bleeding and not induce a systemic activation of
coagulation2 although there has been recent evi-
dence to the contrary.4 It has previously been
argued that FVIIa should not be used in patients
with sepsis, disseminated intravascular coagulation
or extensive tissue damage due to the potential for
excessive clot formation. There are however, case
reports of FVIIa successfully treating life threaten-
ing bleeding after trauma.5,7 Kenet reported a case
of FVIIa controlling massive bleeding from a high
velocity gunshot wound.* Corresponding author. Tel.: +44 1473 712233;
fax: +44 1473 702218.
E-mail address: djmcauley@doctors.org.uk (D. McAuley).
1572-3461 # 2005 Elsevier Ltd. Open access under CC BY-NC-ND license.
doi:10.1016/j.injury.2005.02.040We report, what we believe was, at the time, the
first case of FVIIa being used in the UK to, pre-
emptively, enhance standard haemorrhage control
after a pelvic fracture.Case report
A 30-year-old man was brought by ambulance to the
emergency department 34 min after a crush injury
between a crane and awall at a dockyard. On arrival,
he was talking and alert with initial observations of
heart rate 100 bpm, BP 130/70, respiratory rate 30
and oxygen saturations of 99%. A primary survey
revealed tenderness over the pelvis and blood pre-
sent at the external urethral meatus. On rectal
examination there was a large laceration of the
anterior rectal wall with fragments of bone palp-
able. A pelvis X-ray showed comminuted displaced
bilateral superior and inferior pubic rami fractures
and sacroiliac joint disruption on the left side.
The patient subsequently developed cardiovas-
cular compromise, dropping his blood pressure to
100/50 (heart rate 110). In the first 3 h in hospital he
received 4 l of crystalloid, 3 units of colloid and
6 units of packed cells. At 3 h the patient was taken
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defunctioning colostomy; on induction of anaesthe-
sia he was given a single dose of activated recom-
binant factor VIIa, 7.2 mg (90 mg/kg). Bleeding in
the pelvis was reported by the surgeons as signifi-
cant at the beginning of the operation but had
ceased by the end, three hours later. Haemoglobin
fell from a pre-operative level of 11.9—7.9 1 h into
surgery. During the operation he was given 2.5 l of
colloid and 3 units of packed cells. Other haematol-
ogy parameters preoperatively showed an INR of
1.0, APTT 27, fibrinogen 2.63 and platelet count
257. Post-operatively his results were INR 1.2, APTT
43, fibrinogen 0.93 and platelets 60. During the 24 h
period post operatively he received 5 units of cryo-
precipitate, 1 unit of platelets and 3 units of packed
cells. His clotting parameters returned to normal 3
days after the operation.
His complications in the post operative period
were a bleeding duodenal ulcer requiring urgent
endoscopic injection at day 25, localised pelvic
infection which developed into osteomyelitis with
a fistula still discharging at 18 months and tempor-
ary neuropathic leg pain. There were no clinical
thrombotic events in the 18 months after the injury.Discussion
Recombinant activated factor VII enhances haemos-
tasis at the site of injury by becoming biologically
active only after binding to local tissue factor (TF)
exposed by injury. Haemostasis is then initiated by
the tissue factor (TF)-FVIIa complex through activa-
tion of factors X and IX and finally activating pro-
thrombin to thrombin.
The presence of tissue factor on atherosclerotic
plaques, monocytes and some tumour cells implies a
risk of thromboembolic complications such as myo-
cardial infarction or stroke with the use of rFVIIa in
some patients. There is, likewise, a theoretical risk
in patients with blunt trauma with significant tissue
injury resulting in massive tissue factor exposure.
Martinowitz et al.7 reported a series of patients with
massive haemorrhage, penetrating and blunt, given
rFVIIa after which the bleeding stopped and their
clotting parameters returned to normal. There were
no clinical thromboembolic complications found in
these patients.
Pelvic fractures of the AP compression type II or III
are associated with severe haemorrhage in 28 and
53% cases8 with mortality rates up to 25%.1 Current
treatment options include external fixation and/or
embolization via angiography.
In our patient’s case it is quite possible that his
bleeding would have stopped anyway after applica-tion of the external fixator. However, these injuries
have a high mortality and the greater the blood loss
that occurs (with concomitant replacement using
blood products) the greater the potential for devel-
oping disseminated intravascular coaguloathy (DIC)
or systemic inflammatory response syndrome (SIRS).
An important role for rFVIIa might be as an adjunct,
early after injury, to attenuate or prevent the cycle
of haemorrhage leading to hypothermia, acidosis
and coagulopathy which can lead to further hae-
morrhage, DIC, SIRS, multi-organ failure and death.
The optimum dose required is unknown. The
short half life of 3 h suggests that multiple doses
may be needed. Our patient received only one dose
with apparent good effect. Recombinant FVIIa is
being trialled on a named patient basis in a number
of trauma centres around the world. A multi-centre,
randomized controlled trial of rFVIIa in the treat-
ment of bleeding in severely injured patients should
be undertaken.Contributors
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